What if peptides didn't need water to remain structurally intact? That question sounds almost absurd when you consider Venus. Its surface is a furnace. Its atmosphere is dominated by carbon dioxide. And its clouds contain concentrated sulfuric acid. Yet new research from scientists at MIT suggests that short peptides can remain intact and adopt stable three-dimensional structures in an environment containing 98% sulfuric acid. The finding doesn't prove that life exists on Venus. It doesn't show that Venusian organisms are using peptides. And it certainly doesn't mean peptides are somehow indestructible. What it does demonstrate is much more scientifically interesting: Some complex biological molecules may be capable of maintaining structure in environments that scientists previously considered extraordinarily hostile to them. That could broaden the places researchers consider when searching for chemistry associated with life. Venus Is About as Far From Earth-Like as You Can Get Venus is often called Earth's sister planet because the two worlds are similar in size and composition. But the similarities largely stop there. Venus has an extremely hot surface and an atmosphere dominated by carbon dioxide. Its cloud layer contains droplets of sulfuric acid, creating an environment vastly different from the aqueous environments in which terrestrial biology operates. Yet the clouds themselves are more intriguing than the surface. At certain altitudes, temperatures and pressures are considerably less extreme than at the surface. That has led some astrobiologists to ask an unusual question: Could Venus' clouds provide an environment where some form of chemistry associated with life could persist? The latest peptide research doesn't answer that question. But it adds another important piece of evidence to the puzzle. The New Discovery: Peptides Survived 98% Sulfuric Acid The study, published in Proceedings of the National Academy of Sciences, examined three peptides in highly concentrated sulfuric acid.

Something significant happened in Washington on September 1, 2026. Congresswoman Nancy Mace introduced the PEPTIDES for Veterans Act, legislation that would direct the Department of Veterans Affairs to formally study peptide-based therapies and their potential applications for veterans. The bill doesn't declare peptides proven. It doesn't approve experimental treatments. And it doesn't immediately give veterans access to peptide therapy. What it does is arguably more interesting: It asks the VA to investigate the subject directly. That could represent an important shift in how experimental peptide therapies are discussed at the federal level. For years, peptide discussions have largely lived in the worlds of research, bodybuilding, biohacking, longevity and online wellness communities. Now the conversation has reached Congress. What Is the PEPTIDES for Veterans Act? The legislation is officially called the Providing Evidence-based Peptide Therapies to Improve Delivery and Expanded Services for Veterans Act, or the PEPTIDES for Veterans Act. It was introduced in the House on September 1, 2026, by Representative Nancy Mace of South Carolina as H.R. 10212. The bill has been referred to the House Committee on Veterans' Affairs. Its central objective is straightforward: Direct the VA to investigate the potential benefits, safety and therapeutic applications of peptide-based therapies for veterans receiving VA care. That's an important distinction. The legislation isn't saying: "Peptides work." It's effectively saying: "There is enough interest in this area to justify formally studying the evidence." That is a very different claim. And scientifically, it's the more responsible one. What Would the VA Actually Have to Do? Under the proposed legislation, the VA would first conduct a comprehensive review of existing regulations and guidance surrounding peptide therapies. The bill then calls for an 18-month study examining peptide-based therapies across several potential areas, including:

Your body has its own built-in antimicrobial defense system. Long before antibodies and other parts of the adaptive immune response become fully engaged, the innate immune system is already working to recognize and respond to potential threats. One of the molecules involved in that first line of defense is LL-37. LL-37 is a naturally occurring human host-defense peptide and the only known human member of the cathelicidin family. It has been detected in tissues exposed to the outside environment, including the skin, gastrointestinal tract and respiratory system, and is produced by several types of immune and epithelial cells. What makes LL-37 particularly interesting is that its biological activity appears to extend far beyond simply damaging microbes. Researchers have investigated its potential roles in: - Antibacterial defense - Antifungal activity - Antiviral responses - Immune-cell recruitment - Inflammatory signaling - Cell migration - Angiogenesis - Wound repair That combination has made LL-37 one of the more fascinating host-defense peptides in experimental research. But there is an important distinction throughout this article: LL-37's biological activity is well documented in experimental research. That does not mean LL-37 is an approved treatment for infections, wounds or any other medical condition. What Exactly Is LL-37? LL-37 is a 37-amino-acid antimicrobial peptide derived from a larger precursor protein called human cathelicidin antimicrobial protein 18, or hCAP18. It belongs to a broader group of molecules known as host-defense peptides (HDPs). These peptides are interesting because they can perform multiple biological functions at the same time. They can interact directly with microorganisms while also influencing the cells and signaling pathways involved in the host's immune response. That makes LL-37 less like a conventional single-purpose antimicrobial molecule and more like a multifunctional component of innate immunity.

GLP-1-based therapies have transformed metabolic medicine. Their ability to reduce appetite, improve glycemic control and produce substantial weight loss has made compounds such as semaglutide and tirzepatide some of the most closely watched therapies in modern metabolic research. But as their use has expanded, researchers have also started identifying less common complications that deserve attention. One of the most important recent examples involves Wernicke encephalopathy (WE), a neurological disorder associated with severe thiamine, or vitamin B1, deficiency. A 2026 study published in Clinical Nutrition examined the potential relationship between GLP-1 receptor agonists and Wernicke encephalopathy using pharmacovigilance data and a literature review. The researchers identified 15 cases associated with GLP-1 receptor agonist treatment. Most involved semaglutide or tirzepatide, and 13 of the 15 cases included gastrointestinal symptoms, weight loss, reduced appetite or malnutrition. The study also found that long-term neurological sequelae were reported in 7 of the 11 cases with available follow-up information. That doesn't mean GLP-1 drugs have been proven to directly cause Wernicke encephalopathy. It does, however, raise an important safety question: What happens when powerful appetite suppression, prolonged gastrointestinal symptoms and inadequate nutritional intake occur together for an extended period? First: What Is Wernicke Encephalopathy? Wernicke encephalopathy is a neurological disorder caused by severe thiamine deficiency. Thiamine is vitamin B1, an essential micronutrient involved in carbohydrate metabolism and energy production. The brain has a particularly high energy demand. When thiamine availability becomes severely depleted, several biochemical processes required for normal neurological function can become impaired. The resulting neurological syndrome can include: - Confusion or altered mental status - Problems with coordination and balance - Abnormal eye movements or visual disturbances

There is a strange claim making the rounds in peptide and nootropic communities: “BPC-157 made my Adderall feel like it stopped working.” It is an interesting claim because there is actually a legitimate scientific reason to investigate the question—but the internet has moved considerably faster than the evidence. BPC-157 is an experimental 15-amino-acid peptide that has been studied extensively in animal models, particularly around tissue protection, gastrointestinal biology, vascular signaling and nervous-system effects. Importantly, some preclinical research has also found interactions between BPC-157 and dopaminergic systems. That does not, however, establish that BPC-157 reduces the effects of Adderall or other prescription stimulants in humans. So where did this idea come from? And is there enough science behind it to explain why some people report that their stimulant medication suddenly feels weaker, flatter, or different? Let's separate the interesting pharmacology from the speculation. Research disclaimer: BPC-157 is an experimental compound, and the evidence discussed here is predominantly preclinical. Reports that BPC-157 changes the subjective effects of prescription stimulants are anecdotal and do not establish a drug interaction. This article is educational only and does not provide dosing or treatment advice. Anyone taking prescription medication should discuss potential interactions with their clinician. The Claim: “BPC-157 Blunts Stimulants” The claim usually goes something like this: Someone takes a prescription stimulant such as Adderall, then begins using BPC-157. They subsequently notice that their medication doesn't produce the same subjective effect. They might describe: - less stimulation - reduced motivation - less noticeable focus - a flatter emotional response - lower energy - or, in some cases, feelings described online as anhedonia Some users consequently conclude that BPC-157 must be suppressing dopamine. That conclusion is much stronger than the evidence allows.